# Soleus Capital Management, L.P. 13F Q2 2026: $2.9 billion

Soleus Capital Management, L.P. reported $2.9 billion in 13F securities across 97 positions for the quarter ended June 30, 2026, in a holdings report filed August 11, 2026. Its largest holding was Krystal Biotech Inc at $349 million, 12.0% of the reported value. Since Q1 2026 it opened 22 new positions and exited 18.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $2,901,979,696
- Positions: 97
- Filed: August 11, 2026
- Report type: 13F holdings report
- CIK: 1802630
- Form 13F file number: 028-20043
- Business address: 100 Field Point Road Suite 200, Greenwich, CT 06830
- SEC filing: [0001802630-26-000005](https://www.sec.gov/Archives/edgar/data/1802630/000180263026000005/0001802630-26-000005-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/soleus-capital-management-l-p-294459)

## Top 25 holdings by value

The largest of 97 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Krystal Biotech Inc](https://specstream.ai/data/institutional-holders/krystal-biotech-inc-501147102) | COM | 939,254 | $349.1 million | -213,833 |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102k100) | COM | 1,704,318 | $178.3 million | +419,940 |
| [TG Therapeutics Inc](https://specstream.ai/data/institutional-holders/tg-therapeutics-inc-88322q108) | COM | 2,927,895 | $160.9 million | -1,101,424 |
| [Insulet Corp](https://specstream.ai/data/institutional-holders/insulet-corp-45784p101) | COM | 1,049,000 | $159.7 million | +486,500 |
| [Novocure LTD](https://specstream.ai/data/institutional-holders/novocure-ltd-g6674u108) | ORD SHS | 9,913,401 | $150.2 million | -578,990 |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 225,587 | $122.2 million | +38,400 |
| [Inspire Med Sys Inc](https://specstream.ai/data/institutional-holders/inspire-med-sys-inc-457730109) | COM | 1,931,436 | $86.2 million | +1,355,137 |
| [Rigel Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rigel-pharmaceuticals-inc-766559702) | COM | 1,843,504 | $72.1 million | +1,833,504 |
| [Ani Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/ani-pharmaceuticals-inc-00182c103) | COM | 867,760 | $71.8 million | +47,517 |
| [Beta Bionics Inc](https://specstream.ai/data/institutional-holders/beta-bionics-inc-08659b102) | COM | 4,393,714 | $68.8 million | +39,213 |
| [Vericel Corp](https://specstream.ai/data/institutional-holders/vericel-corp-92346j108) | COM | 1,459,152 | $64.9 million | -1,089,927 |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 177,517 | $59.4 million | -153,000 |
| [Geron Corp](https://specstream.ai/data/institutional-holders/geron-corp-374163103) | COM | 42,808,659 | $54.8 million | +1,300,000 |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 1,029,252 | $53.9 million | -941,612 |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 2,700,000 | $49.5 million | New |
| [Neuropace Inc](https://specstream.ai/data/institutional-holders/neuropace-inc-641288105) | COM | 2,911,122 | $46.3 million | -21,085 |
| [Progyny Inc](https://specstream.ai/data/institutional-holders/progyny-inc-74340e103) | COM | 1,602,000 | $46.2 million | -465,000 |
| [Indivior Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/indivior-pharmaceuticals-inc-45579u109) | COM | 1,064,000 | $43.7 million | -210,000 |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 1,465,070 | $40.1 million | New |
| [Edap TMS S a](https://specstream.ai/data/institutional-holders/edap-tms-s-a-268311107) | SPONSORED ADR | 7,309,254 | $37.9 million | No change |
| [Globus Med Inc](https://specstream.ai/data/institutional-holders/globus-med-inc-379577208) | CL A | 468,922 | $37 million | -260,545 |
| [Arcus Biosciences Inc](https://specstream.ai/data/institutional-holders/arcus-biosciences-inc-03969f109) | COM | 1,168,738 | $36 million | +716,755 |
| [Syndax Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/syndax-pharmaceuticals-inc-87164f105) | COM | 1,628,039 | $35.6 million | -98,869 |
| [Nurix Therapeutics Inc](https://specstream.ai/data/institutional-holders/nurix-therapeutics-inc-67080m103) | COM | 1,465,163 | $35.5 million | +527,000 |
| [Legend Biotech Corp](https://specstream.ai/data/institutional-holders/legend-biotech-corp-52490g102) | SPONSORED ADS | 1,205,000 | $34.8 million | New |

## New positions in Q2 2026

22 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 2,700,000 | $49.5 million |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 1,465,070 | $40.1 million |
| [Legend Biotech Corp](https://specstream.ai/data/institutional-holders/legend-biotech-corp-52490g102) | SPONSORED ADS | 1,205,000 | $34.8 million |
| [Unitedhealth Group Inc](https://specstream.ai/data/institutional-holders/unitedhealth-group-inc-91324p102) | COM | 80,000 | $33.3 million |
| [Palisade Bio Inc](https://specstream.ai/data/institutional-holders/palisade-bio-inc-696389402) | COM | 13,063,687 | $27.3 million |
| [Supernus Pharmaceuticals](https://specstream.ai/data/institutional-holders/supernus-pharmaceuticals-868459108) | COM | 520,000 | $24.2 million |
| [Nuvectis Pharma Inc](https://specstream.ai/data/institutional-holders/nuvectis-pharma-inc-67080t108) | COM | 1,000,000 | $18.4 million |
| [Capricor Therapeutics Inc](https://specstream.ai/data/institutional-holders/capricor-therapeutics-inc-14070b309) | COM NEW | 761,737 | $18.3 million |
| [Prelude Therapeutics Inc](https://specstream.ai/data/institutional-holders/prelude-therapeutics-inc-74065p101) | COM | 3,378,378 | $18 million |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 419,000 | $13.8 million |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 147,000 | $13.1 million |
| [Nektar Therapeutics](https://specstream.ai/data/institutional-holders/nektar-therapeutics-640268306) | COM NEW | 128,362 | $9 million |
| [Artivion Inc](https://specstream.ai/data/institutional-holders/artivion-inc-228903100) | COM | 388,000 | $8.7 million |
| [Belite Bio Inc](https://specstream.ai/data/institutional-holders/belite-bio-inc-07782b104) | SPONSORED ADS | 50,524 | $7.8 million |
| [Silence Therapeutics PLC](https://specstream.ai/data/institutional-holders/silence-therapeutics-plc-82686q101) | ADS | 630,000 | $6.9 million |
| [Immunic Inc](https://specstream.ai/data/institutional-holders/immunic-inc-4525ep200) | COM NEW | 450,000 | $6.9 million |
| [Adlai Nortye LTD](https://specstream.ai/data/institutional-holders/adlai-nortye-ltd-00704r109) | SPONSORED ADS | 405,523 | $4.7 million |
| [Zentalis Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/zentalis-pharmaceuticals-inc-98943l107) | COM | 950,000 | $4.6 million |
| [Arrivent Biopharma Inc](https://specstream.ai/data/institutional-holders/arrivent-biopharma-inc-04272n102) | COM | 50,000 | $1.7 million |
| [Solid Biosciences Inc](https://specstream.ai/data/institutional-holders/solid-biosciences-inc-83422e204) | COM NEW | 150,000 | $1.5 million |
| [Genedx Holdings Corp](https://specstream.ai/data/institutional-holders/genedx-holdings-corp-81663l200) | COM CL A | 10,000 | $686,500 |
| [Equillium Inc](https://specstream.ai/data/institutional-holders/equillium-inc-29446k106) | COM | 90,000 | $288,000 |

## Positions exited in Q2 2026

18 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 385,472 | $22.4 million |
| [Icon PLC](https://specstream.ai/data/institutional-holders/icon-plc-g4705a100) | SHS | 192,000 | $21.2 million |
| [Travere Therapeutics Inc](https://specstream.ai/data/institutional-holders/travere-therapeutics-inc-89422g107) | COM | 546,000 | $16.2 million |
| [Inhibrx Biosciences Inc](https://specstream.ai/data/institutional-holders/inhibrx-biosciences-inc-45720n103) | COM | 131,000 | $8.8 million |
| [Dexcom Inc](https://specstream.ai/data/institutional-holders/dexcom-inc-252131107) | COM | 140,000 | $8.8 million |
| Immunic Inc | COM | 4,500,000 | $5 million |
| [Eton Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/eton-pharmaceuticals-inc-29772l108) | COM | 166,381 | $4.1 million |
| [Arrowhead Pharmaceuticals in](https://specstream.ai/data/institutional-holders/arrowhead-pharmaceuticals-in-04280a100) | COM | 28,479 | $1.8 million |
| [Cytomx Therapeutics Inc.](https://specstream.ai/data/institutional-holders/cytomx-therapeutics-inc-23284f105) | COM | 300,000 | $1.4 million |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 10,000 | $384,900 |
| [Tyra Biosciences Inc](https://specstream.ai/data/institutional-holders/tyra-biosciences-inc-90240b106) | COM | 10,000 | $383,000 |
| [Staar Surgical Co](https://specstream.ai/data/institutional-holders/staar-surgical-co-852312305) | COM PAR $0.01 | 20,000 | $374,000 |
| [Anaptysbio Inc](https://specstream.ai/data/institutional-holders/anaptysbio-inc-032724106) | COM | 6,000 | $332,760 |
| [Rapport Therapeutics Inc](https://specstream.ai/data/institutional-holders/rapport-therapeutics-inc-75383l102) | COM | 10,000 | $312,900 |
| [Zymeworks Inc](https://specstream.ai/data/institutional-holders/zymeworks-inc-98985y108) | COM | 10,000 | $250,400 |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 10,000 | $246,600 |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 5,000 | $245,250 |
| [Jasper Therapeutics Inc](https://specstream.ai/data/institutional-holders/jasper-therapeutics-inc-471871202) | COM NEW | 276,312 | $242,105 |

## Also on SpecStream

- [Soleus Capital Management, L.P. Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1802630/000180263026000005/0001802630-26-000005-index.htm)
- [Soleus Capital Management, L.P. investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/soleus-capital-management-l-p-294459)
- [Largest 13F filers in Connecticut](https://specstream.ai/data/institutional-holdings/state/connecticut)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Greenwich, Connecticut

- [Financial advisory firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/financial-advisory-firms/greenwich-connecticut-united-states)
- [Real estate firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/real-estate-firms/greenwich-connecticut-united-states)
- [Financial services firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/financial-services-firms/greenwich-connecticut-united-states)
- [Banks and credit unions in Greenwich, Connecticut](https://specstream.ai/data/businesses/banks-and-credit-unions/greenwich-connecticut-united-states)
- [Interior design firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/interior-design-firms/greenwich-connecticut-united-states)
- [Contractors in Greenwich, Connecticut](https://specstream.ai/data/businesses/contractors/greenwich-connecticut-united-states)
